COVID-19 mRNA vaccines are safe and effective in children aged 5 to 11 years
1. In a systematic review and meta-analysis of randomized trials and cohort studies in children 5 to 11 years old, ...
Tag: mRNA vaccine
Moderna mRNA COVID-19 vaccine is safe in children six months to five years of age
1. Two doses of the Moderna coronavirus disease 2019 (COVID-19) vaccine were not associated with a significant increase in serious ...
Triple mRNA vaccination and previous COVID-19 exposure provide protection against the omicron variant
1. In this retrospective cohort study among prison residents and staff, mRNA vaccination and previous exposure provided more protection against ...
COVID-19 adenoviral but not mRNA vaccines are associated with adverse cardiovascular events
1. The first dose of adenoviral-based Oxford-AstraZeneca and Janssen vaccines was associated with acute myocardial infarction and pulmonary embolism. 2. ...
Maternal vaccination linked to lower coronavirus disease-related hospitalizations in infants
1. Vaccination during pregnancy with two doses of mRNA vaccine was associated with reduced risk of hospitalization, intensive care unit ...
![The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]](https://www.2minutemedicine.com/wp-content/uploads/2013/05/web-cover-classics-with-logo-medicine-BW-small-jpg-350x250.jpg){kind=logo}
Nationwide vaccination campaign with BNT162b2 mRNA vaccine reports high immunogenicity across all age groups [Classics Series]
This study summary is an excerpt from the book 2 Minute Medicine's The Classics in Medicine: Summaries of the Landmark ...
BNT162b2 mRNA vaccine for COVID-19 prevention [Classics Series]
This study summary is an excerpt from the book 2 Minute Medicine's The Classics in Medicine: Summaries of the Landmark ...
Third dose of BNT162b2 COVID-19 vaccine effective at decreasing risk of hospitalization
1. Compared to two doses of the BNT162b2 vaccine, a third booster dose was estimated to be 93% effective against ...
Heterologous ChAdOx1 prime-boosted vaccination schedules are non-inferior to homologous vaccination
1. Heterologous AstraZeneca followed by Pfizer vaccination was noninferior to homologous, two-dose AstraZeneca vaccination with a geometric mean ratio of ...
